BRPI0908887A2 - composição farmacêutica líquida, recipiente farmacêutico, métodos para preparar e para fabricar uma composição farmacêutica, e, uso de uma composição farmacêutica - Google Patents
composição farmacêutica líquida, recipiente farmacêutico, métodos para preparar e para fabricar uma composição farmacêutica, e, uso de uma composição farmacêuticaInfo
- Publication number
- BRPI0908887A2 BRPI0908887A2 BRPI0908887A BRPI0908887A BRPI0908887A2 BR PI0908887 A2 BRPI0908887 A2 BR PI0908887A2 BR PI0908887 A BRPI0908887 A BR PI0908887A BR PI0908887 A BRPI0908887 A BR PI0908887A BR PI0908887 A2 BRPI0908887 A2 BR PI0908887A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- composition
- pharmaceutical
- preparing
- manufacturing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000007788 liquid Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 abstract 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 229960000686 benzalkonium chloride Drugs 0.000 abstract 1
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940028334 follicle stimulating hormone Drugs 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08151231 | 2008-02-08 | ||
| EP08151231.1 | 2008-02-08 | ||
| PCT/EP2009/051451 WO2009098318A1 (en) | 2008-02-08 | 2009-02-09 | Liquid formulation of fsh |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0908887A2 true BRPI0908887A2 (pt) | 2015-09-15 |
| BRPI0908887B1 BRPI0908887B1 (pt) | 2021-01-19 |
| BRPI0908887B8 BRPI0908887B8 (pt) | 2021-05-25 |
Family
ID=40568186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0908887A BRPI0908887B8 (pt) | 2008-02-08 | 2009-02-09 | composição farmacêutica líquida, recipiente farmacêutico, e, métodos para preparar e para fabricar uma composição farmacêutica |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20110054410A1 (pt) |
| EP (2) | EP2249869B1 (pt) |
| JP (1) | JP5620824B2 (pt) |
| KR (2) | KR101573773B1 (pt) |
| CN (3) | CN101970010A (pt) |
| AT (1) | ATE523209T1 (pt) |
| AU (1) | AU2009211331B2 (pt) |
| BR (1) | BRPI0908887B8 (pt) |
| CA (2) | CA2926500A1 (pt) |
| CY (1) | CY1112082T1 (pt) |
| DE (1) | DE202009009905U1 (pt) |
| DK (1) | DK2249869T3 (pt) |
| EA (1) | EA019530B1 (pt) |
| ES (1) | ES2372470T3 (pt) |
| HR (1) | HRP20110801T1 (pt) |
| IL (1) | IL206759A (pt) |
| ME (1) | ME01337B (pt) |
| MX (1) | MX2010008802A (pt) |
| NZ (1) | NZ586588A (pt) |
| PL (1) | PL2249869T3 (pt) |
| PT (1) | PT2249869E (pt) |
| RS (1) | RS52106B (pt) |
| SI (1) | SI2249869T1 (pt) |
| UA (1) | UA99337C2 (pt) |
| WO (1) | WO2009098318A1 (pt) |
| ZA (1) | ZA201004457B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| PH12011502708B1 (en) | 2009-07-06 | 2017-11-10 | Sanofi Aventis Deutschland | Insulin preparations containing methionine |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| JP5800527B2 (ja) * | 2010-03-30 | 2015-10-28 | 日東電工株式会社 | 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法 |
| AR081755A1 (es) | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ２型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| MX2014005204A (es) * | 2011-11-09 | 2014-05-28 | Adisseo France Sas | Dieta previa al sacrificio que incluye metionina. |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| CN105727260A (zh) * | 2016-02-03 | 2016-07-06 | 华侨大学 | 一种卵泡刺激素的长效制剂 |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| CN105726468A (zh) * | 2016-02-28 | 2016-07-06 | 中国农业科学院特产研究所 | 梅花鹿用超数排卵聚乙烯吡咯烷酮fsh复合缓释注射剂 |
| US10085971B2 (en) | 2016-08-22 | 2018-10-02 | Navinta Iii Inc | Pharmaceutical solution of asenapine for sublingual or buccal use |
| CN108728465A (zh) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用 |
| CN111686079A (zh) * | 2019-11-28 | 2020-09-22 | 成都泽研生物技术有限公司 | 卵泡刺激素冻干制剂及其制备方法和用途 |
| US20230364172A1 (en) * | 2022-05-14 | 2023-11-16 | Syncotrance, LLC | Modulation of solubility, palatability, absorption, and bioavailability of mitragyna speciosa-derived compounds for oral and buccal delivery |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4840896A (en) | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| US4923805A (en) | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| CA2018676C (en) | 1989-06-20 | 2003-05-06 | Christie A. Kelton | Novel heteropolymeric protein production methods |
| DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
| DE4440587A1 (de) | 1994-11-14 | 1996-05-15 | Fliether Karl Gmbh & Co | Basquill-Schloß |
| TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| AU747179B2 (en) | 1997-06-25 | 2002-05-09 | Merck Serono Sa | Disulfide cross-linked glycoprotein hormone analogs, their preparation and use |
| US20030166525A1 (en) * | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
| CA2335340C (en) * | 1998-07-23 | 2013-03-05 | Eli Lilly And Company | Fsh and fsh variant formulations, products and methods |
| ATE358139T1 (de) | 1999-04-16 | 2007-04-15 | Inst Massone S A | Verfahren zur herstelllung von gonadotropin- zusammensetzungen |
| WO2001058493A1 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | Conjugates of follicle stimulating hormones |
| DE10249817A1 (de) | 2002-10-24 | 2004-05-13 | Daimlerchrysler Ag | Schaltanordnung zur Betätigung von Beleuchtungssystemen an einem Kraftfahrzeug |
| WO2004087213A1 (en) * | 2003-04-02 | 2004-10-14 | Ares Trading S.A. | Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
| ATE446314T1 (de) | 2003-12-22 | 2009-11-15 | Ares Trading Sa | Methode zur reinigung von fsh |
| EP1809663B1 (en) | 2004-11-09 | 2008-09-17 | Ares Trading S.A. | Method for purifying fsh |
| KR101105871B1 (ko) | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| CN101720332B (zh) | 2007-06-28 | 2014-08-13 | 拉蒂奥法姆有限责任公司 | 生产促卵泡激素的细胞克隆 |
-
2009
- 2009-02-09 RS RS20110505A patent/RS52106B/sr unknown
- 2009-02-09 SI SI200930091T patent/SI2249869T1/sl unknown
- 2009-02-09 KR KR1020107018371A patent/KR101573773B1/ko active Active
- 2009-02-09 DE DE202009009905U patent/DE202009009905U1/de not_active Expired - Lifetime
- 2009-02-09 BR BRPI0908887A patent/BRPI0908887B8/pt active IP Right Grant
- 2009-02-09 CN CN2009801040855A patent/CN101970010A/zh active Pending
- 2009-02-09 JP JP2010545495A patent/JP5620824B2/ja active Active
- 2009-02-09 NZ NZ586588A patent/NZ586588A/xx not_active IP Right Cessation
- 2009-02-09 WO PCT/EP2009/051451 patent/WO2009098318A1/en not_active Ceased
- 2009-02-09 HR HR20110801T patent/HRP20110801T1/hr unknown
- 2009-02-09 CA CA2926500A patent/CA2926500A1/en not_active Abandoned
- 2009-02-09 KR KR1020157033736A patent/KR101662631B1/ko active Active
- 2009-02-09 ME MEP-2011-182A patent/ME01337B/me unknown
- 2009-02-09 EP EP09708298A patent/EP2249869B1/en active Active
- 2009-02-09 PL PL09708298T patent/PL2249869T3/pl unknown
- 2009-02-09 PT PT09708298T patent/PT2249869E/pt unknown
- 2009-02-09 CN CN201510082820.4A patent/CN104688679A/zh active Pending
- 2009-02-09 CN CN201910216104.9A patent/CN110433136A/zh active Pending
- 2009-02-09 AU AU2009211331A patent/AU2009211331B2/en active Active
- 2009-02-09 DK DK09708298.6T patent/DK2249869T3/da active
- 2009-02-09 US US12/866,736 patent/US20110054410A1/en not_active Abandoned
- 2009-02-09 AT AT09708298T patent/ATE523209T1/de active
- 2009-02-09 ES ES09708298T patent/ES2372470T3/es active Active
- 2009-02-09 EP EP11179767A patent/EP2412385A1/en not_active Withdrawn
- 2009-02-09 CA CA2713386A patent/CA2713386C/en not_active Expired - Fee Related
- 2009-02-09 MX MX2010008802A patent/MX2010008802A/es unknown
- 2009-02-09 EA EA201070940A patent/EA019530B1/ru not_active IP Right Cessation
- 2009-02-09 UA UAA201010809A patent/UA99337C2/ru unknown
-
2010
- 2010-06-24 ZA ZA2010/04457A patent/ZA201004457B/en unknown
- 2010-07-01 IL IL206759A patent/IL206759A/en active IP Right Grant
-
2011
- 2011-11-24 CY CY20111101150T patent/CY1112082T1/el unknown
-
2016
- 2016-06-29 US US15/196,430 patent/US20160303201A1/en not_active Abandoned
- 2016-06-29 US US15/196,460 patent/US20160303202A1/en not_active Abandoned
- 2016-06-29 US US15/196,440 patent/US20160303238A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112082T1 (el) | Υγρη φαρμακοτεχνικη μορφη fsh | |
| MY196599A (en) | Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| WO2006138181A3 (en) | Self-buffering protein formulations | |
| WO2012160180A3 (en) | Pharmaceutical composition for administration to nails | |
| BRPI0924460A2 (pt) | composição farmacêutica para uso em oftalmologia médica e veterinária | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| NO20100301L (no) | Forbedrete brimonidinsammensetninger for behandling av erytem | |
| WO2011146808A3 (en) | Topical formulation for a jak inhibitor | |
| CO6761350A2 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| MX2011012143A (es) | Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas. | |
| WO2007059979A3 (en) | Allergy treatment by epicutaneous allergen administration | |
| WO2008136034A3 (en) | Ophthalmic compositions for the treatment of ocular hypertension and glaucoma | |
| BRPI0413186A (pt) | composição de fexofenadina e processo para preparação da mesma | |
| BRPI0510449A (pt) | uso de formulações de meloxicam em medicina veterinária | |
| BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| CA3264923A1 (en) | COMPOSITION INTENDED FOR USE IN THE TREATMENT OF FABRY'S DISEASE | |
| CO7170181A2 (es) | Nueva composición de alfentanilo para el tratamiento del dolor agudo | |
| CL2008002060A1 (es) | Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras. | |
| BRPI0418743A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| RU2012135798A (ru) | Фармацевтическая композиция для лечения зуда кожи | |
| EP4681784A3 (en) | Pharmaceutical composition for use in improving quality of scalp or skin, wound healing, or improving quality of hair | |
| JP2017222676A5 (pt) | ||
| WO2012071480A3 (en) | Lipophilic glucocorticosteroid monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging | |
| CA3303242A1 (en) | Pharmaceutical composition for use in the disease treatments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25D | Requested change of name of applicant approved |
Owner name: BIOGENERIX GMBH (DE) |
|
| B25A | Requested transfer of rights approved |
Owner name: RATIOPHARM GMBH (DE) |
|
| B25A | Requested transfer of rights approved |
Owner name: THERAMEX HQ UK LIMITED (GB) |
|
| B25G | Requested change of headquarter approved |
Owner name: THERAMEX HQ UK LIMITED (GB) |
|
| B25G | Requested change of headquarter approved |
Owner name: THERAMEX HQ UK LIMITED (GB) |